Corrigendum to “The cancer COMPASS: Navigating the functions of MLL complexes in cancer” [Cancer Genetics 208 (2015) pp. 178–191] (The cancer COMPASS: navigating the functions of MLL complexes in cancer (2015) 208(5) (178–191), (S221077621500006X), (10.1016/j.cancergen.2015.01.005));The cancer COMPASS: Navigating the functions of MLL complexes in cancer

Cancer Genetics

Volumn 208, Issue 5, 2015, Pages 178-191

  Ford, David J ^a   Dingwall, Andrew K ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Chromatin; COMPASS complex; Enhancers; Epigenetics; Lysine methyltransferase

Indexed keywords

DNA DIRECTED RNA POLYMERASE III; E1A ASSOCIATED P300 PROTEIN; HISTONE H3; HISTONE METHYLTRANSFERASE; MIXED LINEAGE LEUKEMIA PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN 1; MIXED LINEAGE LEUKEMIA PROTEIN 2; MIXED LINEAGE LEUKEMIA PROTEIN 3; MIXED LINEAGE LEUKEMIA PROTEIN 4; PINOMETOSTAT; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR SNF; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CHROMATIN; DNA BINDING PROTEIN; HISTONE LYSINE METHYLTRANSFERASE; MLL PROTEIN, HUMAN; MLL2 PROTEIN, HUMAN; MLL3 PROTEIN, HUMAN; MLL4 PROTEIN, HUMAN; TUMOR PROTEIN;

ADIPOGENESIS; AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ARTICLE; BINDING SITE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILDHOOD LEUKEMIA; CHROMATIN; COMPLEX FORMATION; DEVELOPMENTAL DISORDER; EPIGENETICS; EXOME; GENE CONTROL; GENE EXPRESSION; GENE FUSION; GENE MUTATION; GENE TRANSLOCATION; GERMLINE MUTATION; HETEROZYGOSITY; HIGH THROUGHPUT SEQUENCING; HISTONE MODIFICATION; HUMAN; LEUKEMIA; MALIGNANT TRANSFORMATION; NEOPLASM; OLIGOMERIZATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SOMATIC CELL; TRANSCRIPTION REGULATION; TUMOR GROWTH; CARCINOMA; CELL TRANSFORMATION; GENETIC EPIGENESIS; GENETICS;

CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LEUKEMIA; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM PROTEINS;

EID: 84930576745     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2019.03.003     Document Type: Erratum

References (177)

1. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
2. Gardner K.E., Allis C.D., Strahl B.D. Operating on chromatin, a colorful language where context matters. JMol Biol 2011, 409:36-46.
3. Wang Y., Li X., Hu H. H3K4me2 reliably defines transcripti Caenorhabditis elegans on factor binding regions in different cells. Genomics 2014, 103:222-228.
4. Calo E., Wysocka J. Modification of enhancer chromatin: what, how, and why?. Mol Cell 2013, 49:825-837.
5. Allis C.D., Berger S.L., Cote J., et al. New nomenclature for chromatin-modifying enzymes. Cell 2007, 131:633-636.
6. Bögershausen N., Bruford E., Wollnik B. Skirting the pitfalls: a clear-cut nomenclature for H3K4 methyltransferases. Clin Genet 2013, 83:212-214.
7. Shilatifard A. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu Rev Biochem 2012, 81:65-95.
8. Kusch T. Histone H3 lysine 4 methylation revisited. Transcription 2012, 3:310-314.
9. Herz H.M., Garruss A., Shilatifard A. SET for life: biochemical activities and biological functions of SET domain-containing proteins. Trends Biochem Sci 2013, 38:621-639.
10. van Nuland R., Smits A.H., Pallaki P., et al. Quantitative dissection and stoichiometry determination of the human SET1/MLL histone methyltransferase complexes. Mol Cell Biol 2013, 33:2067-2077.
11. Ardehali M.B., Mei A., Zobeck K.L., et al. Drosophila Set1 is the major histone H3 lysine 4 trimethyltransferase with role in transcription. EMBO J 2011, 30:2817-2828.
12. Herz H.M., Mohan M., Garruss A.S., et al. Enhancer-associated H3K4 monomethylation by Trithorax-related, the Drosophila homolog of mammalian Mll3/Mll4. Genes Dev 2012, 26:2604-2620.
13. Hu D., Gao X., Morgan M.A., et al. The MLL3/MLL4 Branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers. Mol Cell Biol 2013, 33:4745-4754.
14. Hu D., Garruss A.S., Gao X., et al. The Mll2 branch of the COMPASS family regulates bivalent promoters in mouse embryonic stem cells. Nat Struct Mol Biol 2013, 20:1093-1097.
15. Simon J.A., Tamkun J.W. Programming off and on states in chromatin: mechanisms of Polycomb and Trithorax group complexes. Curr Opin Genet Dev 2002, 12:210-218.
16. Schuettengruber B., Chourrout D., Vervoort M., et al. Genome regulation by polycomb and Trithorax proteins. Cell 2007, 128:735-745.
17. Wang P., Lin C., Smith E.R., et al. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol Cell Biol 2009, 29:6074-6085.
18. Bernstein B.E., Mikkelsen T.S., Xie X., et al. Abivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006, 125:315-326.
19. Voigt P., Tee W.W., Reinberg D. Adouble take on bivalent promoters. Genes Dev 2013, 27:1318-1338.
20. Chauhan C., Zraly C.B., Dingwall A.K. The Drosophila COMPASS-like Cmi-Trr coactivator complex regulates dpp/BMP signaling in pattern formation. Dev Biol 2013, 380:185-198.
21. Kanda H., Nguyen A., Chen L., et al. The Drosophila ortholog of MLL3 and MLL4, Trithorax related, functions as a negative regulator of tissue growth. Mol Cell Biol 2013, 33:1702-1710.
22. Lee J.E., Wang C., Xu S., et al. H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation. eLife 2013, 2:e01503.
23. Lee J.H., Tate C.M., You J.S., et al. Identification and characterization of the human Set1B histone H3-Lys4 methyltransferase complex. JBiol Chem 2007, 282:13419-13428.
24. Yu B.D., Hess J.L., Horning S.E., et al. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 1995, 378:505-508.
25. Glaser S., Schaft J., Lubitz S., et al. Multiple epigenetic maintenance factors implicated by the loss of Mll2 in mouse development. Development 2006, 133:1423-1432.
26. Lubitz S., Glaser S., Schaft J., et al. Increased apoptosis and skewed differentiation in mouse embryonic stem cells lacking the histone methyltransferase Mll2. Mol Biol Cell 2007, 18:2356-2366.
27. Yagi H., Deguchi K., Aono A., et al. Growth disturbance in fetal liver hematopoiesis of Mll-mutant mice. Blood 1998, 92:108-117.
28. Ernst P., Fisher J.K., Avery W., et al. Definitive hematopoiesis requires the mixed-lineage leukemia gene. Dev Cell 2004, 6:437-443.
29. Goo Y.H., Sohn Y.C., Kim D.H., et al. Activating signal cointegrator 2 belongs to a novel steady-state complex that contains a subset of Trithorax group proteins. Mol Cell Biol 2003, 23:140-149.
30. Mo R., Rao S.M., Zhu Y.J. Identification of the MLL2 complex as a coactivator for estrogen receptor alpha. JBiol Chem 2006, 281:15714-15720.
31. Guo C., Chang C.C., Wortham M., et al. Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways. Proc Natl Acad Sci U S A 2012, 109:17603-17608.
32. Lee J., Kim D.H., Lee S., et al. Atumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc Natl Acad Sci U S A 2009, 106:8513-8518.
33. Ziemin-van der Poel S., McCabe N.R., Gill H.J., et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci U S A 1991, 88:10735-10739.
34. Ballabio E., Milne T.A. Molecular and epigenetic mechanisms of MLL in human leukemogenesis. Cancers (Basel) 2012, 4:904-944.
35. Somervaille T.C., Cleary M.L. Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?. Int J Hematol 2010, 91:735-741.
36. Chang P.Y., Hom R.A., Musselman C.A., et al. Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription. JMol Biol 2010, 400:137-144.
37. Chung Y.R., Schatoff E., Abdel-Wahab O. Epigenetic alterations in hematopoietic malignancies. Int J Hematol 2012, 96:413-427.
38. Ansari K.I., Kasiri S., Mandal S.S. Histone methylase MLL1 has critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth invivo. Oncogene 2013, 32:3359-3370.
39. Wu M., Shu H.B. MLL1/WDR5 complex in leukemogenesis and epigenetic regulation. Chin J Cancer 2011, 30:240-246.
40. Li B.E., Ernst P. Two decades of leukemia oncoprotein epistasis: the Mixed Lineage Leukemia paradigm for epigenetic deregulation in leukemia. Exp Hematol 2014, 42:995-1012.
41. Saigo K., Yoshida K., Ikeda R., et al. Integration of hepatitis B virus DNA into the myeloid/lymphoid or mixed-lineage leukemia (MLL4) gene and rearrangements of MLL4 in human hepatocellular carcinoma. Hum Mutat 2008, 29:703-708.
42. Tamori A., Nishiguchi S., Shiomi S., et al. Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus. Am J Gastroenterol 2005, 100:1748-1753.
43. O'Meara E., Stack D., Phelan S., et al. Identification of an MLL4-GPS2 fusion as an oncogenic driver of undifferentiated spindle cell sarcoma in a child. Genes Chromosomes Cancer 2014, 53:991-998.
44. Huntsman D.G., Chin S.F., Muleris M., et al. MLL2, the second human homolog of the Drosophila Trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines. Oncogene 1999, 18:7975-7984.
45. Ruault M., Brun M.E., Ventura M., et al. MLL3, a new human member of the TRX/MLL gene family, maps to 7q36, a chromosome region frequently deleted in myeloid leukaemia. Gene 2002, 284:73-81.
46. Dolnik A., Engelmann J.C., Scharfenberger-Schmeer M., et al. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. Blood 2012, 120:e83-e92.
47. Chen C., Liu Y., Rappaport A.R., et al. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 2014, 25:652-665.
48. Li W.D., Li Q.R., Xu S.N., et al. Exome sequencing identifies an MLL3 gene germ line mutation in a pedigree of colorectal cancer and acute myeloid leukemia. Blood 2013, 121:1478-1479.
49. Balakrishnan A., Bleeker F.E., Lamba S., et al. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res 2007, 67:3545-3550.
50. Biankin A.V., Waddell N., Kassahn K.S., et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012, 491:399-405.
51. Ong C.K., Subimerb C., Pairojkul C., et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet 2012, 44:690-693.
52. Fujimoto A., Totoki Y., Abe T., et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012, 44:760-764.
53. Zang Z.J., Cutcutache I., Poon S.L., et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012, 44:570-574.
54. Li B., Liu H.Y., Guo S.H., et al. Mll3 genetic variants affect risk of gastric cancer in the Chinese Han population. Asian Pac J Cancer Prev 2013, 14:4239-4242.
55. Pickering C.R., Zhou J.H., Lee J.J., et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res 2014, 20:6582-6592.
56. Li B., Liu H.Y., Guo S.H., et al. Association of MLL3 expression with prognosis in gastric cancer. Genet Mol Res 2014, 13:7513-7518.
57. Dalgliesh G.L., Furge K., Greenman C., et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463:360-363.
58. Buck M.J., Raaijmakers L.M., Ramakrishnan S., et al. Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma. Oncogene 2013, 33:4961-4965.
59. Morin R.D., Mendez-Lago M., Mungall A.J., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476:298-303.
60. Stransky N., Egloff A.M., Tward A.D., et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160.
61. Lawrence M.S., Stojanov P., Mermel C.H., et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014, 505:495-501.
62. Green M.R., Gentles A.J., Nair R.V., et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 2013, 121:1604-1611.
63. Okosun J., Bödör C., Wang J., et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 2014, 46:176-181.
64. Beà S., Valdés-Mas R., Navarro A., et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A 2013, 110:18250-18255.
65. Huether R., Dong L., Chen X., et al. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun 2014, 5:3630.
66. Yin S., Yang J., Lin B., et al. Exome sequencing identifies frequent mutation of MLL2 in non-small cell lung carcinoma from Chinese patients. Sci Rep 2014, 4:6036.
67. Ross J.S., Wang K., Elkadi O.R., et al. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. JClin Pathol 2014, 67:772-776.
68. Ansari K.I., Hussain I., Kasiri S., et al. HOXC10 is overexpressed in breast cancer and transcriptionally regulated by estrogen via involvement of histone methylases MLL3 and MLL4. JMol Endocrinol 2012, 48:61-75.
69. Bhan A., Hussain I., Ansari K.I., et al. Histone methyltransferase EZH2 is transcriptionally induced by estradiol as well as estrogenic endocrine disruptors bisphenol-A and diethylstilbestrol. JMol Biol 2014, 426:3426-3441.
70. Ellis M.J., Ding L., Shen D., et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012, 486:353-360.
71. Kim J.H., Sharma A., Dhar S.S., et al. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. Cancer Res 2014, 74:1705-1717.
72. Rabello Ddo A., de Moura C.A., de Andrade R.V., et al. Altered expression of MLL methyltransferase family genes in breast cancer. Int J Oncol 2013, 43:653-660.
73. Wang X.X., Fu L., Li X., et al. Somatic mutations of the mixed-lineage leukemia 3 (MLL3) gene in primary breast cancers. Pathol Oncol Res 2011, 17:429-433.
74. Parsons D.W., Li M., Zhang X., et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011, 331:435-439.
75. Pugh T.J., Weeraratne S.D., Archer T.C., et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012, 488:106-110.
76. Song Y., Li L., Ou Y., et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature 2014, 509:91-95.
77. Kandoth C., McLellan M.D., Vandin F., et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502:333-339.
78. Moreira A.L., Won H.H., McMillan R., et al. Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis. JThorac Oncol 2015, 10:373-380.
79. Martin D., Abba M.C., Molinolo A.A., et al. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. Oncotarget 2014, 5:8906-8923.
80. Gao Y.B., Chen Z.L., Li J.G., et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet 2014, 46:1097-1102.
81. Lindberg J., Mills I.G., Klevebring D., et al. The mitochondrial and autosomal mutation landscapes of prostate cancer. Eur Urol 2013, 63:702-708.
82. Grasso C.S., Wu Y.M., Robinson D.R., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
83. Fukuda K., Sakakura C., Miyagawa K., et al. Differential gene expression profiles of radioresistant oesophageal cancer cell lines established by continuous fractionated irradiation. Br J Cancer 2004, 91:1543-1550.
84. Kanchi K.L., Johnson K.J., Lu C., et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun 2014, 5:3156.
85. Mouradov D., Sloggett C., Jorissen R.N., et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res 2014, 74:3238-3247.
86. Shin N., You K.T., Lee H., et al. Identification of frequently mutated genes with relevance to nonsense mediated mRNA decay in the high microsatellite instability cancers. Int J Cancer 2011, 128:2872-2880.
87. Ashktorab H., Schäffer A.A., Daremipouran M., et al. Distinct genetic alterations in colorectal cancer. PLoS One 2010, 5:e8879.
88. Ibragimova I., Dulaimi E., Slifker M.J., et al. Aglobal profile of gene promoter methylation in treatment-naive urothelial cancer. Epigenetics 2014, 9:760-773.
89. Van der Meulen J., Speleman F., Van Vlierberghe P. The H3K27me3 demethylase UTX in normal development and disease. Epigenetics 2014, 9:658-668.
90. Miyake N., Koshimizu E., Okamoto N., et al. MLL2 and KDM6A mutations in patients with Kabuki syndrome. Am J Med Genet A 2013, 161A:2234-2243.
91. Copur O., Muller J. The histone H3-K27 demethylase Utx regulates HOX gene expression in Drosophila in a temporally restricted manner. Development 2013, 140:3478-3485.
92. Tarayrah L., Herz H.M., Shilatifard A., et al. Histone demethylase dUTX antagonizes JAK-STAT signaling to maintain proper gene expression and architecture of the Drosophila testis niche. Development 2013, 140:1014-1023.
93. Chauhan C., Zraly C.B., Parilla M., et al. Histone recognition and nuclear receptor co-activator functions of Drosophila cara mitad, a homolog of the N-terminal portion of mammalian MLL2 and MLL3. Development 2012, 139:1997-2008.
94. Liu J., Mercher T., Scholl C., et al. Afunctional role for the histone demethylase UTX in normal and malignant hematopoietic cells. Exp Hematol 2012, 40:487-498.e3.
95. Mar B.G., Bullinger L., Basu E., et al. Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. Leukemia 2012, 26:1881-1883.
96. Rocha-Viegas L., Villa R., Gutierrez A., et al. Role of UTX in retinoic acid receptor-mediated gene regulation in leukemia. Mol Cell Biol 2014, 34:3765-3775.
97. Ntziachristos P., Tsirigos A., Welstead G.G., et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 2014, 514:513-517.
98. Gui Y., Guo G., Huang Y., et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011, 43:875-878.
99. Nickerson M.L., Dancik G.M., Im K.M., et al. Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer. Clin Cancer Res 2014, 20:4935-4948.
100. Paolicchi E., Crea F., Farrar W.L., et al. Histone lysine demethylases in breast cancer. Crit Rev Oncol Hematol 2013, 86:97-103.
101. Shen Y., Guo X., Wang Y., et al. Expression and significance of histone H3K27 demethylases in renal cell carcinoma. BMC Cancer 2012, 12:470.
102. Morin R.D., Johnson N.A., Severson T.M., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010, 42:181-185.
103. Wagener N., Macher-Goeppinger S., Pritsch M., et al. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 2010, 10:524.
104. Kleer C.G., Cao Q., Varambally S., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003, 100:11606-11611.
105. Varambally S., Dhanasekaran S.M., Zhou M., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
106. Simon J.A., Lange C.A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008, 647:21-29.
107. Mahajan M.A., Samuels H.H. Nuclear receptor coactivator/coregulator NCoA6(NRC) is a pleiotropic coregulator involved in transcription, cell survival, growth and development. Nucl Recept Signal 2008, 6:e002.
108. Antonson P., Schuster G.U., Wang L., et al. Inactivation of the nuclear receptor coactivator RAP250 in mice results in placental vascular dysfunction. Mol Cell Biol 2003, 23:1260-1268.
109. Mahajan M.A., Das S., Zhu H., et al. The nuclear hormone receptor coactivator NRC is a pleiotropic modulator affecting growth, development, apoptosis, reproduction, and wound repair. Mol Cell Biol 2004, 24:4994-5004.
110. Kuang S.Q., Liao L., Zhang H., et al. Deletion of the cancer-amplified coactivator AIB3 results in defective placentation and embryonic lethality. JBiol Chem 2002, 277:45356-45360.
111. Oh H., Slattery M., Ma L., et al. Yorkie promotes transcription by recruiting a histone methyltransferase complex. Cell Rep 2014, 8:449-459.
112. Qing Y., Yin F., Wang W., et al. The Hippo effector Yorkie activates transcription by interacting with a histone methyltransferase complex through Ncoa6. eLife 2014, 3:e02564.
113. Wang Z., Yan Z., Zhang B., et al. Identification of a 5-gene signature for clinical and prognostic prediction in gastric cancer patients upon microarray data. Med Oncol 2013, 30:678.
114. Patel S.R., Kim D., Levitan I., et al. The BRCT-domain containing protein PTIP links PAX2 to a histone H3, lysine 4 methyltransferase complex. Dev Cell 2007, 13:580-592.
115. Cho Y.W., Hong T., Hong S., et al. PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4 methyltransferase complex. JBiol Chem 2007, 282:20395-20406.
116. Kleefstra T., Kramer J.M., Neveling K., et al. Disruption of an EHMT1-associated chromatin-modification module causes intellectual disability. Am J Hum Genet 2012, 91:73-82.
117. Lee S., Kim D.H., Goo Y.H., et al. Crucial roles for interactions between MLL3/4 and INI1 in nuclear receptor transactivation. Mol Endocrinol 2009, 23:610-619.
118. Bokinni Y. Kabuki syndrome revisited. JHum Genet 2012, 57:223-227.
119. Bogershausen N., Wollnik B. Unmasking kabuki syndrome. Clin Genet 2013, 83:201-211.
120. Shinsky S.A., Hu M., Vought V.E., et al. Anon-active-site SET domain surface crucial for the interaction of MLL1 and the RbBP5/Ash2L heterodimer within MLL family core complexes. JMol Biol 2014, 426:2283-2299.
121. Lee S., Lee D.K., Dou Y., et al. Coactivator as a target gene specificity determinant for histone H3 lysine 4 methyltransferases. Proc Natl Acad Sci U S A 2006, 103:15392-15397.
122. Lee J., Saha P.K., Yang Q.H., et al. Targeted inactivation of MLL3 histone H3-Lys-4 methyltransferase activity in the mouse reveals vital roles for MLL3 in adipogenesis. Proc Natl Acad Sci U S A 2008, 105:19229-19234.
123. Kim D.H., Rhee J.C., Yeo S., et al. Crucial roles of MLL3 and MLL4 as epigenetic switches of the hepatic circadian clock controlling bile acid homeostasis. Hepatology 2014, 61:1012-1023.
124. Issaeva I., Zonis Y., Rozovskaia T., et al. Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth. Mol Cell Biol 2006, 27:1889-1903.
125. Li T., Kelly W.G. Arole for Set1/MLL-related components in epigenetic regulation of the Caenorhabditis elegans germ line. PLoS Genet 2011, 7:e1001349.
126. Mohan M., Herz H.M., Smith E.R., et al. The COMPASS family of H3K4 methylases in Drosophila. Mol Cell Biol 2011, 31:4310-4318.
127. Sedkov Y., Cho E., Petruk S., et al. Methylation at lysine 4 of histone H3 in ecdysone-dependent development of Drosophila. Nature 2003, 426:78-83.
128. Barron D.A., Kagey J.D. The role of the Hippo pathway in human disease and tumorigenesis. Clin Transl Med 2014, 3:25.
129. Massague J. TGFbeta in cancer. Cell 2008, 134:215-230.
130. Ntziachristos P., Lim J.S., Sage J., et al. From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell 2014, 25:318-334.
131. Herz H.M., Hu D., Shilatifard A. Enhancer malfunction in cancer. Mol Cell 2014, 53:859-866.
132. Valekunja U.K., Edgar R.S., Oklejewicz M., et al. Histone methyltransferase MLL3 contributes to genome-scale circadian transcription. Proc Natl Acad Sci U S A 2013, 110:1554-1559.
133. Sparmann A., van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006, 6:846-856.
134. Wilson B.G., Wang X., Shen X., et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 2010, 18:316-328.
135. Dawson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
136. Margueron R., Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011, 469:343-349.
137. Guo C., Chen L.H., Huang Y., et al. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget 2013, 4:2144-2153.
138. Daigle S.R., Olhava E.J., Therkelsen C.A., et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013, 122:1017-1025.
139. Gonzalez-Perez A., Jene-Sanz A., Lopez-Bigas N. The mutational landscape of chromatin regulatory factors across 4,623 tumor samples. Genome Biol 2013, 14:r106.
140. Lindqvist C.M., Nordlund J., Ekman D., et al. The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing. Hum Mutat 2015, 36:118-128.
141. Stephens P.J., Tarpey P.S., Davies H., et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012, 486:400-404.
142. Hodis E., Watson I.R., Kryukov G.V., et al. Alandscape of driver mutations in melanoma. Cell 2012, 150:251-263.
143. Peifer M., Fernández-Cuesta L., Sos M.L., et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012, 44:1104-1110.
144. Dulak A.M., Stojanov P., Peng S., et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013, 45:478-486.
145. Seshagiri S., Stawiski E.W., Durinck S., et al. Recurrent R-spondin fusions in colon cancer. Nature 2012, 488:660-664.
146. Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
147. Guo G., Sun X., Chen C., et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013, 45:1459-1463.
148. Iyer G., Al-Ahmadie H., Schultz N., et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. JClin Oncol 2013, 31:3133-3140.
149. Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507:315-322.
150. Jones S., Stransky N., McCord C.L., et al. Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nat Commun 2014, 5:5006.
151. Krauthammer M., Kong Y., Ha B.H., et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012, 44:1006-1014.
152. Imielinski M., Berger A.H., Hammerman P.S., et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150:1107-1120.
153. Hao C., Wang L., Peng S., et al. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett 2015, 357:179-185.
154. Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
155. Agrawal N., Frederick M.J., Pickering C.R., et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 333:1154-1157.
156. Guo G., Gui Y., Gao S., et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 2012, 44:17-19.
157. Cancer Genome Atlas Research Network Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499:43-49.
158. Cancer Genome Atlas Research Network, Kandoth C., Schultz N., et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497:67-73.
159. Jones D.T., Stransky N., McCord C.L., et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012, 488:100-105.
160. Robinson G., Parker M., Kranenburg T.A., et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012, 488:43-48.
161. Dubuc A.M., Remke M., Korshunov A., et al. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol 2013, 125:373-384.
162. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
163. Ahn S.M., Jang S.J., Shim J.H., et al. Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 2014, 60:1972-1982.
164. Banerji S., Cibulskis K., Rangel-Escareno C., et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012, 486:405-409.
165. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
166. Taylor B.S., Schultz N., Hieronymus H., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
167. Barbieri C.E., Taubert H., Gaisa N.T., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012, 44:685-689.
168. Baca S.C., Prandi D., Lawrence M.S., et al. Punctuated evolution of prostate cancer genomes. Cell 2013, 153:666-677.
169. Rudin C.M., Durinck S., Stawiski E.W., et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012, 44:1111-1116.
170. Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. Erratum in: Nature 2013 Feb 28;494:506.
171. Brennan C.W., Verhaak R.G., McKenna A., et al. The somatic genomic landscape of glioblastoma. Cell 2013, 155:462-477.
172. Cancer Genome Atlas Research Network Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. NEngl J Med 2013, 368:2059-2074.
173. Lohr J.G., Stojanov P., Carter S.L., et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014, 25:91-101.
174. Ho A.S., Kannan K., Roy D.M., et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet 2013, 45:791-798.
175. Cerami E., Gao J., Dogrusoz U., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012, 2:401-404.
176. Gao J., Aksoy B.A., Dogrusoz U., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013, 6:pl1.
177. Ren J., Wen L., Gao X., et al. DOG 1.0: illustrator of protein domain structures. Cell Res 2009, 19:271-273.